Switch theme
Sign up to access all valuation multiples
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
2016
36
LTM Revenue $1.0M
LTM EBITDA -$117M
$795M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oculis Holding has a last 12-month revenue (LTM) of $1.0M and a last 12-month EBITDA of -$117M.
In the most recent fiscal year, Oculis Holding achieved revenue of n/a and an EBITDA of -$84.9M.
Oculis Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oculis Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $1.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$117M | XXX | -$84.9M | XXX | XXX | XXX |
| EBITDA Margin | -11366% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$106M | XXX | -$73.2M | XXX | XXX | XXX |
| EBIT Margin | -10327% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$119M | XXX | -$85.8M | XXX | XXX | XXX |
| Net Margin | -11601% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oculis Holding's stock price is $19.
Oculis Holding has current market cap of $1.0B, and EV of $795M.
See Oculis Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $795M | $1.0B | XXX | XXX | XXX | XXX | $-2.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oculis Holding has market cap of $1.0B and EV of $795M.
Oculis Holding's trades at n/a EV/Revenue multiple, and -9.4x EV/EBITDA.
Equity research analysts estimate Oculis Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oculis Holding has a P/E ratio of -10.2x.
See valuation multiples for Oculis Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $795M | XXX | $795M | XXX | XXX | XXX |
| EV/Revenue | 928.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -8.2x | XXX | -9.4x | XXX | XXX | XXX |
| EV/EBIT | -9.0x | XXX | -10.9x | XXX | XXX | XXX |
| EV/Gross Profit | 928.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.2x | XXX | -11.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOculis Holding's last 12 month revenue growth is 1096%
Oculis Holding's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Oculis Holding's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oculis Holding's rule of X is -8627% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oculis Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1096% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -11366% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -8627% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oculis Holding acquired XXX companies to date.
Last acquisition by Oculis Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Oculis Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oculis Holding founded? | Oculis Holding was founded in 2016. |
| Where is Oculis Holding headquartered? | Oculis Holding is headquartered in United States of America. |
| How many employees does Oculis Holding have? | As of today, Oculis Holding has 36 employees. |
| Who is the CEO of Oculis Holding? | Oculis Holding's CEO is Dr. Riad Sherif, M.D.. |
| Is Oculis Holding publicy listed? | Yes, Oculis Holding is a public company listed on NAS. |
| What is the stock symbol of Oculis Holding? | Oculis Holding trades under OCS ticker. |
| When did Oculis Holding go public? | Oculis Holding went public in 2023. |
| Who are competitors of Oculis Holding? | Similar companies to Oculis Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oculis Holding? | Oculis Holding's current market cap is $1.0B |
| What is the current revenue of Oculis Holding? | Oculis Holding's last 12 months revenue is $1.0M. |
| What is the current revenue growth of Oculis Holding? | Oculis Holding revenue growth (NTM/LTM) is 1096%. |
| What is the current EV/Revenue multiple of Oculis Holding? | Current revenue multiple of Oculis Holding is 928.3x. |
| Is Oculis Holding profitable? | Yes, Oculis Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oculis Holding? | Oculis Holding's last 12 months EBITDA is -$117M. |
| What is Oculis Holding's EBITDA margin? | Oculis Holding's last 12 months EBITDA margin is -11366%. |
| What is the current EV/EBITDA multiple of Oculis Holding? | Current EBITDA multiple of Oculis Holding is -8.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
